Nabriva Therapeutics PLC
Change company Symbol lookup
Select an option...
NBRV Nabriva Therapeutics PLC
CSRLF CSR Ltd
LGIH LGI Homes Inc
ARI Apollo Commercial Real Estate Finance Inc
D Dominion Energy Inc
QTS-A QTS Realty Trust Inc
ICHR Ichor Holdings Ltd
AMRC Ameresco Inc
AVID Avid Technology Inc
NBIX Neurocrine Biosciences Inc
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Pharmaceuticals | Small Cap Growth
Based in Ireland
Company profile

Nabriva Therapeutics plc is a biopharmaceutical company engaged in the commercialization and development of anti-infective agents to treat serious infections. The Company’s product XENLETA (lefamulin), is a semi-synthetic pleuromutilin antibiotic for systematic administration in humans. It inhibits the synthesis of bacterial protein, which is required for bacteria to grow by binding with high affinity, high specificity and at molecular targets that are different than other antibiotic classes. The Company is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.

Closing Price
$0.776
Day's Change
0.016 (2.11%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.7789
Day's Low
0.7503
Volume
(Light)
Volume:
2,205,316

10-day average volume:
5,948,475
2,205,316

Display:

Providers:

UpdateCancel
6 providers
Yesterday's News, August 03, 2020
Nabriva Therapeutics to Report Second Quarter 2020 Financial Results on August 6, 2020

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its second quarter financial...(Globe Newswire)

July 30, 2020
Nabriva Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at...(Globe Newswire)

July 28, 2020
NABRIVA Receives European Approval for XENLETA(R) (lefamulin) for Treatment of Community-Acquired Pneumonia (CAP)

-XENLETA represents the first new antibiotic class approved for patients with CAP in Europe in nearly 20 years -XENLETA approval provides urgently needed short-course, empiric monotherapy treatment option for CAP aligned with core principles of...(Globe Newswire)

July 23, 2020
Lefamulin Demonstrates Anti-Inflammatory Activity in Pre-Clinical Study

-In pre-clinical model, lefamulin shows anti-inflammatory activity comparable to dexamethasone -Nabriva awarded grant funding from the Austrian Research Promotion Agency to further characterize the anti-inflammatory and immunomodulatory properties...(Globe Newswire)

July 22, 2020
U.S. Small Cap Stocks Could Outperform The Market During The Recovery And Here Are Four Stocks You Need To Know About

According to Premier Miton Fund Manager Nick Ford in a recent CNBC's "Squawk Box Europe" interview, U.S. small cap stocks are set to outperform the S&P 500 in the uncertain aftermath of the coronavirus crisis. This is big news for small...(Globe Newswire)

July 16, 2020
XENLETA(R) (lefamulin) Receives Health Canada Approval for Treatment of Community Acquired Pneumonia

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that its partner, Sunovion Pharmaceuticals Canada...(Globe Newswire)

Thinking about buying stock in Plug Power, Nabriva Therapeutics, electroCore Inc, Spirit Airlines, or TOP Ships?

InvestorsObserver issues critical PriceWatch Alerts for PLUG, NBRV, ECOR, SAVE, and TOPS. https://mma.prnewswire.com/media/1086590/InvestorsObserver_Logo.jpg To see how InvestorsObserver's proprietary scoring system rates these stocks, view the...(PR Newswire)

July 15, 2020
Nabriva Therapeutics Enters into Exclusive Agreement to Promote and Distribute SIVEXTRO(R) (tedizolid phosphate) in the U.S.

-- Accretive transaction creates synergies and scale that strengthen Nabriva's community-focused commercialization organization to optimize product uptake -- Nabriva partners with Amplity Health to provide community-focused customer engagement and...(Globe Newswire)

July 06, 2020
WEP Clinical Partners With Nabriva Therapeutics for the Named Patient Supply of XENLETA(R) (lefamulin)

WEP Clinical (WEP), a specialist pharmaceutical services company, has signed an exclusive agreement with Nabriva Therapeutics (Nabriva) to supply XENLETA(R) (lefamulin) on a named patient or expanded access basis. The Named Patient Program (NPP) is...(BusinessWire)

June 19, 2020
Nabriva Therapeutics Receives Complete Response Letter from FDA on NDA for CONTEPO(TM) (fosfomycin) for injection

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that it received a Complete Response Letter (CRL)...(Globe Newswire)

May 29, 2020
Nabriva Therapeutics Announces $38 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has entered into a definitive agreement...(Globe Newswire)

Nabriva Therapeutics Receives Positive EU CHMP Opinion for XENLETA(TM) (lefamulin) for the Treatment of Community-Acquired Pneumonia (CAP)

-- If approved, XENLETA has the potential to be a first-in-class pleuromutilin antibiotic for the intravenous (IV) and oral treatment of adult patients with CAP in Europe -- CHMP opinion supported by robust safety and efficacy data from two global...(Globe Newswire)

May 27, 2020
Nabriva Therapeutics to Present at the Jefferies Virtual Healthcare Conference

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at...(Globe Newswire)

May 18, 2020
National Burden of Macrolide-Resistant Streptococcus Pneumoniae in the United States From Blood and Respiratory Tract Cultures Approaches 40 Percent

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced the publication of a study entitled, A Multicenter...(Globe Newswire)

May 11, 2020
Nabriva Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Updates

-Cash runway extended into the fourth quarter of 2020 through judicious resource management- -XENLETA managed care coverage and patient reimbursement continues to strengthen- -Potential value-creating life cycle management for XENLETA initiated via...(Globe Newswire)

Nabriva Therapeutics to Present at the BofA Securities 2020 Virtual Health Care Conference

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at...(Globe Newswire)

May 08, 2020
Nabriva Therapeutics to Report First Quarter 2020 Financial Results on May 11, 2020

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its first quarter financial...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.